Biohaven Surges on FDA Review Date for SCA Drug, but Approval Remains Uncertain

What happened

Biohaven received a Complete Response Letter from the FDA in November 2025 for troriluzole in spinocerebellar ataxia, leading to a sharp stock decline and strategic restructuring. The company subsequently focused on its Kv7 epilepsy program and degraders while exploring regulatory options for SCA. On October 22, 2026, the FDA set a review date for the SCA drug, likely following a resubmission or new data, causing the stock to surge on volume over four times average. This procedural milestone does not guarantee approval, as the FDA previously raised concerns about the adequacy of clinical evidence. Investors should treat the rally as speculative until the review concludes and the drug's efficacy is validated.

Implication

The stock's rebound on the FDA review date reflects optimism, but the SCA program carries substantial uncertainty given prior regulatory setbacks. Even if approved, troriluzole's commercial potential is constrained by royalty and milestone obligations to Oberland and Yale, limiting free cash flow to equity. Biohaven still faces high cash burn, negative equity, and reliance on dilutive financings, with BHV-7000 epilepsy data in 1H 2026 being the pivotal value driver. Investors should monitor the FDA review outcome and whether management can execute R&D right-sizing to extend runway. Until then, risk remains high and any position should be sized modestly with confirmation from upcoming catalysts.

Thesis delta

The previous thesis assigned minimal value to the SCA program following the CRL, treating it as a failed or abandoned asset. The new FDA review date reintroduces optionality for SCA, but approval is uncertain and financial upside is limited by royalty and debt structures. Consequently, the overall investment thesis remains contingent on BHV-7000 epilepsy success and degrader advancement, with SCA providing only a secondary, low-probability catalyst.